This core body temperature treatment maintains a target temperature for a set duration to prevent tissue damage caused by a steep rise in body temperature following rapid metabolic actions and maintain homeostasis while spontaneous circulation returns after cardiac arrest. Our invention relates to a composition with similar effect of the targeted core body temperature treatment containing klotho protein or genes encoding it as active components. Klotho protein enables to protect tissue damage caused by the rise of body temperature in situations such as ischemia or ischemia-reperfusion injury.
According to the World Health Organization (WHO), ischemic cardiovascular disease causes an average of 16.7 million deaths each year, accounting for one-third of all deaths. Across 30 OECD countries, the number of deaths from circulatory disorder is decreasing, whereas deaths from cardiovascular disease is ranked first. In the Republic of Korea, the mortality rate from ischemic cardiovascular disease is increasing, and is expected to continue increasing in the future, due to risk factors such as westernization of diet, lack of exercise, and aging of the population. Target temperature management (therapeutic hypothermia) is the only treatment that improves neurological prognosis, alleviating brain cell destruction and reperfusion injury by reducing metabolism and oxygen consumption after cardiac arrest. It has been widely used in the Republic of Korea since 2007 as a method of lowering the patient's body temperature with hydrogel pads. This management can be applied to several diseases related to ischemia-reperfusion injury. This invention is expected to be in demand as a promising technology that can show similar effect with target temperature management by administering klotho protein in ischemia-reperfusion injury such as cardiac arrest, acute myocardial infarction and stroke.